FDA approves new antibiotic for skin infections

The Food and Drug Administration has approved a new antibiotic from Durata Therapeutics to treat adults with common skin infections often acquired in U.S. hospitals.

Regulators approved the intravenous drug Dalvance to treat bacterial skin infections caused by common bacteria, including antibiotic-resistant strains of those germs.

The FDA gave Dalvance an expedited review, under a 2012 law designed to encourage research and development of . Under the measure, Chicago-based Durata will receive an additional five years of exclusive marketing rights on the drug.

The FDA said it approved Dalvance based on two trials of nearly 1,300 patients with skin and skin structure infections.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Vibativ approved for certain bacterial pneumonia

Jun 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

18 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.